The Cost of Medications: Current Realities and the Future of Pharmaceutical Pricing Regulations in the United States
From “Pharma Bro” Martin Shkreli to huge price jumps for the EpiPen to the Hepatitis C treatment that costs $1000 per pill, pharmaceutical pricing is a major issue in the news and in Washington. The regular introduction of new, often expensive therapeutics as well as controversial price increases for familiar drugs attract bipartisan attention and ensure that drug costs will remain an important topic of public policy debate.
This panel of experts discussed current laws and regulations governing pharmaceutical pricing in the United States, the impact of breakthrough therapeutics on drug pricing, and the future of drug pricing policy in the United States.
Panelists
-
Aaron S. Kesselheim, Associate Professor of Medicine, Brigham and Women’s Hospital/Harvard Medical School
-
Jorge Lopez, General Counsel, Memorial Sloan Kettering Cancer Center
-
Sabrina Yohai, Vice President, Policy, Access & Value, Vertex Pharmaceuticals
-
Moderator: Carmel Shachar, Executive Director, the Petrie-Flom Center, and Lecturer at Law, Harvard Law School
Sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and the Center for Bioethics at Harvard Medical School, with support from the Oswald DeN. Cammann Fund at Harvard University.
Videos
VIDEO: I. Glenn Cohen, Introduction
VIDEO: Sabrina Yohai, "U.S. Drug Pricing and Reimbursement Ecosystem"
VIDEO: Jorge Lopez, "Controversies and Potential Solutions"
Tags
health care finance health law policy innovation intellectual property medicare-medicaid pharmaceuticals regulation